Chronic Obstructive Pulmonary Disease Market - Global Outlook and Forecast 2021-2027

Table of Contents

1 Introduction to Research & Analysis Reports
1.1 Chronic Obstructive Pulmonary Disease Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Chronic Obstructive Pulmonary Disease Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Chronic Obstructive Pulmonary Disease Overall Market Size
2.1 Global Chronic Obstructive Pulmonary Disease Market Size: 2021 VS 2027
2.2 Global Chronic Obstructive Pulmonary Disease Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Chronic Obstructive Pulmonary Disease Players in Global Market
3.2 Top Global Chronic Obstructive Pulmonary Disease Companies Ranked by Revenue
3.3 Global Chronic Obstructive Pulmonary Disease Revenue by Companies
3.4 Top 3 and Top 5 Chronic Obstructive Pulmonary Disease Companies in Global Market, by Revenue in 2020
3.5 Global Companies Chronic Obstructive Pulmonary Disease Product Type
3.6 Tier 1, Tier 2 and Tier 3 Chronic Obstructive Pulmonary Disease Players in Global Market
3.6.1 List of Global Tier 1 Chronic Obstructive Pulmonary Disease Companies
3.6.2 List of Global Tier 2 and Tier 3 Chronic Obstructive Pulmonary Disease Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Chronic Obstructive Pulmonary Disease Market Size Markets, 2021 & 2027
4.1.2 Bronchodilators
4.1.3 Glucocorticoids
4.1.4 Other
4.2 By Type - Global Chronic Obstructive Pulmonary Disease Revenue & Forecasts
4.2.1 By Type - Global Chronic Obstructive Pulmonary Disease Revenue, 2016-2021
4.2.2 By Type - Global Chronic Obstructive Pulmonary Disease Revenue, 2022-2027
4.2.3 By Type - Global Chronic Obstructive Pulmonary Disease Revenue Market Share, 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Chronic Obstructive Pulmonary Disease Market Size, 2021 & 2027
5.1.2 Prevention
5.1.3 Diagnostic
5.1.4 Treatment
5.2 By Application - Global Chronic Obstructive Pulmonary Disease Revenue & Forecasts
5.2.1 By Application - Global Chronic Obstructive Pulmonary Disease Revenue, 2016-2021
5.2.2 By Application - Global Chronic Obstructive Pulmonary Disease Revenue, 2022-2027
5.2.3 By Application - Global Chronic Obstructive Pulmonary Disease Revenue Market Share, 2016-2027
6 Sights by Region
6.1 By Region - Global Chronic Obstructive Pulmonary Disease Market Size, 2021 & 2027
6.2 By Region - Global Chronic Obstructive Pulmonary Disease Revenue & Forecasts
6.2.1 By Region - Global Chronic Obstructive Pulmonary Disease Revenue, 2016-2021
6.2.2 By Region - Global Chronic Obstructive Pulmonary Disease Revenue, 2022-2027
6.2.3 By Region - Global Chronic Obstructive Pulmonary Disease Revenue Market Share, 2016-2027
6.3 North America
6.3.1 By Country - North America Chronic Obstructive Pulmonary Disease Revenue, 2016-2027
6.3.2 US Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.3.3 Canada Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.3.4 Mexico Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.4 Europe
6.4.1 By Country - Europe Chronic Obstructive Pulmonary Disease Revenue, 2016-2027
6.4.2 Germany Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.4.3 France Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.4.4 U.K. Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.4.5 Italy Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.4.6 Russia Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.4.7 Nordic Countries Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.4.8 Benelux Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.5 Asia
6.5.1 By Region - Asia Chronic Obstructive Pulmonary Disease Revenue, 2016-2027
6.5.2 China Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.5.3 Japan Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.5.4 South Korea Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.5.5 Southeast Asia Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.5.6 India Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.6 South America
6.6.1 By Country - South America Chronic Obstructive Pulmonary Disease Revenue, 2016-2027
6.6.2 Brazil Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.6.3 Argentina Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Chronic Obstructive Pulmonary Disease Revenue, 2016-2027
6.7.2 Turkey Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.7.3 Israel Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.7.4 Saudi Arabia Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
6.7.5 UAE Chronic Obstructive Pulmonary Disease Market Size, 2016-2027
7 Players Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Corporate Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca Chronic Obstructive Pulmonary Disease Major Product Offerings
7.1.4 AstraZeneca Chronic Obstructive Pulmonary Disease Revenue in Global (2016-2021)
7.1.5 AstraZeneca Key News
7.2 GSK
7.2.1 GSK Corporate Summary
7.2.2 GSK Business Overview
7.2.3 GSK Chronic Obstructive Pulmonary Disease Major Product Offerings
7.2.4 GSK Chronic Obstructive Pulmonary Disease Revenue in Global (2016-2021)
7.2.5 GSK Key News
7.3 MSD
7.3.1 MSD Corporate Summary
7.3.2 MSD Business Overview
7.3.3 MSD Chronic Obstructive Pulmonary Disease Major Product Offerings
7.3.4 MSD Chronic Obstructive Pulmonary Disease Revenue in Global (2016-2021)
7.3.5 MSD Key News
7.4 Sunovion
7.4.1 Sunovion Corporate Summary
7.4.2 Sunovion Business Overview
7.4.3 Sunovion Chronic Obstructive Pulmonary Disease Major Product Offerings
7.4.4 Sunovion Chronic Obstructive Pulmonary Disease Revenue in Global (2016-2021)
7.4.5 Sunovion Key News
7.5 Novartis
7.5.1 Novartis Corporate Summary
7.5.2 Novartis Business Overview
7.5.3 Novartis Chronic Obstructive Pulmonary Disease Major Product Offerings
7.5.4 Novartis Chronic Obstructive Pulmonary Disease Revenue in Global (2016-2021)
7.5.5 Novartis Key News
7.6 Roche Group
7.6.1 Roche Group Corporate Summary
7.6.2 Roche Group Business Overview
7.6.3 Roche Group Chronic Obstructive Pulmonary Disease Major Product Offerings
7.6.4 Roche Group Chronic Obstructive Pulmonary Disease Revenue in Global (2016-2021)
7.6.5 Roche Group Key News
7.7 Pfizer
7.7.1 Pfizer Corporate Summary
7.7.2 Pfizer Business Overview
7.7.3 Pfizer Chronic Obstructive Pulmonary Disease Major Product Offerings
7.4.4 Pfizer Chronic Obstructive Pulmonary Disease Revenue in Global (2016-2021)
7.7.5 Pfizer Key News
7.8 Jubilant Pharma Limited
7.8.1 Jubilant Pharma Limited Corporate Summary
7.8.2 Jubilant Pharma Limited Business Overview
7.8.3 Jubilant Pharma Limited Chronic Obstructive Pulmonary Disease Major Product Offerings
7.8.4 Jubilant Pharma Limited Chronic Obstructive Pulmonary Disease Revenue in Global (2016-2021)
7.8.5 Jubilant Pharma Limited Key News
7.9 Almirall
7.9.1 Almirall Corporate Summary
7.9.2 Almirall Business Overview
7.9.3 Almirall Chronic Obstructive Pulmonary Disease Major Product Offerings
7.9.4 Almirall Chronic Obstructive Pulmonary Disease Revenue in Global (2016-2021)
7.9.5 Almirall Key News
7.10 Horizon Pharma
7.10.1 Horizon Pharma Corporate Summary
7.10.2 Horizon Pharma Business Overview
7.10.3 Horizon Pharma Chronic Obstructive Pulmonary Disease Major Product Offerings
7.10.4 Horizon Pharma Chronic Obstructive Pulmonary Disease Revenue in Global (2016-2021)
7.10.5 Horizon Pharma Key News
7.11 Boehringer Ingelheim
7.11.1 Boehringer Ingelheim Corporate Summary
7.11.2 Boehringer Ingelheim Business Overview
7.11.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Major Product Offerings
7.11.4 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Revenue in Global (2016-2021)
7.11.5 Boehringer Ingelheim Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer


List of Tables
Table 1. Chronic Obstructive Pulmonary Disease Market Opportunities & Trends in Global Market
Table 2. Chronic Obstructive Pulmonary Disease Market Drivers in Global Market
Table 3. Chronic Obstructive Pulmonary Disease Market Restraints in Global Market
Table 4. Key Players of Chronic Obstructive Pulmonary Disease in Global Market
Table 5. Top Chronic Obstructive Pulmonary Disease Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Chronic Obstructive Pulmonary Disease Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Chronic Obstructive Pulmonary Disease Revenue Share by Companies, 2016-2021
Table 8. Global Companies Chronic Obstructive Pulmonary Disease Product Type
Table 9. List of Global Tier 1 Chronic Obstructive Pulmonary Disease Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Chronic Obstructive Pulmonary Disease Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type - Global Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Chronic Obstructive Pulmonary Disease Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Chronic Obstructive Pulmonary Disease Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application - Global Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Chronic Obstructive Pulmonary Disease Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Chronic Obstructive Pulmonary Disease Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region - Global Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Chronic Obstructive Pulmonary Disease Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Chronic Obstructive Pulmonary Disease Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2022-2027
Table 30. AstraZeneca Corporate Summary
Table 31. AstraZeneca Chronic Obstructive Pulmonary Disease Product Offerings
Table 32. AstraZeneca Chronic Obstructive Pulmonary Disease Revenue (US$, Mn), (2016-2021)
Table 33. GSK Corporate Summary
Table 34. GSK Chronic Obstructive Pulmonary Disease Product Offerings
Table 35. GSK Chronic Obstructive Pulmonary Disease Revenue (US$, Mn), (2016-2021)
Table 36. MSD Corporate Summary
Table 37. MSD Chronic Obstructive Pulmonary Disease Product Offerings
Table 38. MSD Chronic Obstructive Pulmonary Disease Revenue (US$, Mn), (2016-2021)
Table 39. Sunovion Corporate Summary
Table 40. Sunovion Chronic Obstructive Pulmonary Disease Product Offerings
Table 41. Sunovion Chronic Obstructive Pulmonary Disease Revenue (US$, Mn), (2016-2021)
Table 42. Novartis Corporate Summary
Table 43. Novartis Chronic Obstructive Pulmonary Disease Product Offerings
Table 44. Novartis Chronic Obstructive Pulmonary Disease Revenue (US$, Mn), (2016-2021)
Table 45. Roche Group Corporate Summary
Table 46. Roche Group Chronic Obstructive Pulmonary Disease Product Offerings
Table 47. Roche Group Chronic Obstructive Pulmonary Disease Revenue (US$, Mn), (2016-2021)
Table 48. Pfizer Corporate Summary
Table 49. Pfizer Chronic Obstructive Pulmonary Disease Product Offerings
Table 50. Pfizer Chronic Obstructive Pulmonary Disease Revenue (US$, Mn), (2016-2021)
Table 51. Jubilant Pharma Limited Corporate Summary
Table 52. Jubilant Pharma Limited Chronic Obstructive Pulmonary Disease Product Offerings
Table 53. Jubilant Pharma Limited Chronic Obstructive Pulmonary Disease Revenue (US$, Mn), (2016-2021)
Table 54. Almirall Corporate Summary
Table 55. Almirall Chronic Obstructive Pulmonary Disease Product Offerings
Table 56. Almirall Chronic Obstructive Pulmonary Disease Revenue (US$, Mn), (2016-2021)
Table 57. Horizon Pharma Corporate Summary
Table 58. Horizon Pharma Chronic Obstructive Pulmonary Disease Product Offerings
Table 59. Horizon Pharma Chronic Obstructive Pulmonary Disease Revenue (US$, Mn), (2016-2021)
Table 60. Boehringer Ingelheim Corporate Summary
Table 61. Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Product Offerings
Table 62. Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Revenue (US$, Mn), (2016-2021)
List of Figures
Figure 1. Chronic Obstructive Pulmonary Disease Segment by Type
Figure 2. Chronic Obstructive Pulmonary Disease Segment by Application
Figure 3. Global Chronic Obstructive Pulmonary Disease Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Chronic Obstructive Pulmonary Disease Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Chronic Obstructive Pulmonary Disease Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Chronic Obstructive Pulmonary Disease Revenue in 2020
Figure 8. By Type - Global Chronic Obstructive Pulmonary Disease Revenue Market Share, 2016-2027
Figure 9. By Application - Global Chronic Obstructive Pulmonary Disease Revenue Market Share, 2016-2027
Figure 10. By Region - Global Chronic Obstructive Pulmonary Disease Revenue Market Share, 2016-2027
Figure 11. By Country - North America Chronic Obstructive Pulmonary Disease Revenue Market Share, 2016-2027
Figure 12. US Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Chronic Obstructive Pulmonary Disease Revenue Market Share, 2016-2027
Figure 16. Germany Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 17. France Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Chronic Obstructive Pulmonary Disease Revenue Market Share, 2016-2027
Figure 24. China Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 28. India Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Chronic Obstructive Pulmonary Disease Revenue Market Share, 2016-2027
Figure 30. Brazil Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Chronic Obstructive Pulmonary Disease Revenue Market Share, 2016-2027
Figure 33. Turkey Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Chronic Obstructive Pulmonary Disease Revenue, (US$, Mn), 2016-2027
Figure 37. AstraZeneca Chronic Obstructive Pulmonary Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. GSK Chronic Obstructive Pulmonary Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. MSD Chronic Obstructive Pulmonary Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. Sunovion Chronic Obstructive Pulmonary Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Novartis Chronic Obstructive Pulmonary Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Roche Group Chronic Obstructive Pulmonary Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. Pfizer Chronic Obstructive Pulmonary Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. Jubilant Pharma Limited Chronic Obstructive Pulmonary Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 45. Almirall Chronic Obstructive Pulmonary Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 46. Horizon Pharma Chronic Obstructive Pulmonary Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 47. Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Revenue Year Over Year Growth (US$, Mn) & (2016-2021)

AstraZeneca
GSK
MSD
Sunovion
Novartis
Roche Group
Pfizer
Jubilant Pharma Limited
Almirall
Horizon Pharma
Boehringer Ingelheim